Meet South Dakota couple who became quiet force behind state’s newest public company
“The future is as big as you can imagine.” And they helped make it so. Meet the local couple behind this incredible startup success story.
“The future is as big as you can imagine.” And they helped make it so. Meet the local couple behind this incredible startup success story.
Sioux Falls-based SAB Biotherapeutics officially is a publicly traded company.
Based on data that shows it’s safe and effective, the COVID-19 therapeutic developed by Sioux Falls-based SAB Biotherapeutics has moved into phase three of clinical trials.
The federal government has awarded additional funding of $60.5 million to Sioux Falls-based SAB Biotherapeutics as it advances its treatment for COVID-19.
“We see this as a one-of-a-kind opportunity, and it stood out.” Out of 60 companies, how a Sioux Falls biotech business became the one to take public.
The treatment developed by Sioux Falls-based SAB Biotherapeutics for the virus that causes COVID-19 has shown “effective and potent” ability to neutralize multiple variants of concern, including the Delta and Lambda variants.
SAB Biotherapeutics co-founder and CEO Eddie Sullivan is among 11 winners of the Ernst & Young Entrepreneur of the Year Heartland Award.
SAB Biotherapeutics is moving ahead with clinical trials for its influenza treatment.
Sioux Falls-based SAB Biotherapeutics plans to merge with a Miami-based firm, which will allow it to trade on the Nasdaq.
SAB Biotherapeutics CEO and co-founder Eddie Sullivan is a finalist for a regional Ernst & Young LLP Entrepreneur of the Year award.